BI
PRVL

BVF Inc’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

BVF Inc’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-431,483
Closed -$5.26M – 65
2020
Q1 		$5.26M Sell
431,483
-225,000
-34% -$3.58M 0.49% 38
2019
Q4 		$10.4M Hold
656,483
– – 0.79% 30
2019
Q3 		$8.06M Hold
656,483
– – 0.85% 34
2019
Q2 		$8.67M Buy
+656,483
New +$9.57M 0.95% 34

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc's PRVL Position: Q2 2020 in Review

BVF Inc sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q2 2020, closing a stake of 431,483 shares — an estimated $5.26M sold.

BVF Inc first reported a position in PRVL in Q2 2019 and held it in 4 quarters. The position peaked at $10.4M in Q4 2019. 67 funds tracked by Wall St. Rank hold PRVL as of Q2 2020.

  • BVF Inc reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • BVF Inc sold 431,483 Prevail Therapeutics Inc. Common Stock shares in Q2 2020, an estimated $5.26M.
  • BVF Inc first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • BVF Inc's Prevail Therapeutics Inc. Common Stock position peaked at $10.4M in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q2 2020.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.